Ewa Paszkiewicz‐Kozik

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 245 citations

Interim Analysis, Lymphoid Neoplasia, Medicine +8

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Massimo Federico, María Dolores Caballero Barrigón, Luigi Marcheselli et al. · The Lancet Haematology · 2018 · 112 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +5

Degradation of NF-κB in T Cells by Gangliosides Expressed on Renal Cell Carcinomas

Mark Thornton, Daisuke Kudo, Patricia Rayman et al. · The Journal of Immunology · 2004 · 52 citations · Full text

Renal Cell Carcinoma Tumors Induce T Cell Apoptosis through Receptor-Dependent and Receptor-Independent Pathways

Tanya Das, Gaurisankar Sa, Ewa Paszkiewicz‐Kozik et al. · The Journal of Immunology · 2008 · 42 citations

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · Journal of Clinical Oncology · 2020 · 34 citations

Cell Therapy, Pd-1 Blockade, Immunology +18